Search ( 3940 results )
- article
(Updated on )
Opinion of the High Council for Public Health regarding the mandatory minimum information requirements for advertising the Varilrix® chickenpox vaccine.
- article
(Updated on )
Opinion of the High Council for Public Health regarding the mandatory minimum information requirements for advertising the Varivax® chickenpox vaccine.
- article
(Updated on )
Opinion of the High Council for Public Health regarding the use of the tetravalent meningococcal conjugate vaccine A, C, Y, W135 (Menveo®).
- article
(Updated on )
Opinion of the High Council for Public Health on vaccination against human papillomavirus infections for girls aged 14 to 23.
- article
(Updated on )
Supplementary opinion of the High Council for Public Health regarding the use of the tetravalent meningococcal conjugate vaccine A, C, Y, W135 (Menveo®).
- article
(Updated on )
Opinion of the High Council for Public Health regarding the minimum mandatory information for advertising the tetravalent meningococcal conjugate vaccine A, C, Y, W135 Menveo®.
- article
(Updated on )
Opinion of the High Council for Public Health regarding the mandatory minimum information requirements for advertising the quadrivalent human papillomavirus vaccine Gardasil®.
- article
(Updated on )
Opinion of the High Council for Public Health regarding the mandatory minimum information requirements for advertising the bivalent human papillomavirus vaccine Cervarix®.
- article
(Updated on )
Invasive meningococcal infections in France in 2008
Introduction - For more than 20 years, the annual incidence rate of invasive meningococcal disease (IMD) in France has ranged from 1 to 2 cases per 105 inhabitants. Methods -...
- article
(Updated on )
Actual age at the time of MMR vaccination in France in 2007
Background - Since measles-mumps-rubella (MMR) vaccination coverage in France was deemed insufficient, the MMR vaccination policy was revised in 2005 to maintain a high level of...
